This subgroup analysis evaluated the efficacy and safety of fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide, in patients with migraine and obesity (body mass index [BMI] ≥30 kg/m2 [BMI-high]).
No takes yet. Share an insight, caveat, or question.
Sieira et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: